495.83
price up icon2.40%   11.61
after-market Dopo l'orario di chiusura: 495.83
loading
Precedente Chiudi:
$484.22
Aprire:
$487.01
Volume 24 ore:
1.36M
Relative Volume:
0.92
Capitalizzazione di mercato:
$127.47B
Reddito:
$11.02B
Utile/perdita netta:
$-535.60M
Rapporto P/E:
-225.38
EPS:
-2.2
Flusso di cassa netto:
$-978.00M
1 W Prestazione:
+4.48%
1M Prestazione:
-1.77%
6M Prestazione:
+2.27%
1 anno Prestazione:
+25.04%
Intervallo 1D:
Value
$484.20
$498.64
Intervallo di 1 settimana:
Value
$452.00
$498.64
Portata 52W:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Nome
Vertex Pharmaceuticals Inc
Name
Telefono
(617) 341-6393
Name
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Name
Dipendente
6,100
Name
Cinguettio
@VertexPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
VRTX's Discussions on Twitter

Confronta VRTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
495.83 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.06 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
606.39 36.98B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.01 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
242.75 26.15B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-12 Aggiornamento Canaccord Genuity Sell → Hold
2025-02-11 Aggiornamento Canaccord Genuity Sell → Hold
2025-01-30 Downgrade Wells Fargo Overweight → Equal Weight
2024-12-20 Reiterato H.C. Wainwright Buy
2024-12-19 Downgrade Oppenheimer Outperform → Perform
2024-12-09 Aggiornamento Jefferies Hold → Buy
2024-11-14 Iniziato Citigroup Buy
2024-10-16 Iniziato Scotiabank Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-05 Downgrade Barclays Overweight → Equal Weight
2024-06-27 Iniziato Redburn Atlantic Buy
2024-04-11 Aggiornamento Evercore ISI In-line → Outperform
2024-02-15 Iniziato Wolfe Research Outperform
2024-02-06 Downgrade Evercore ISI Outperform → In-line
2024-02-02 Downgrade Bernstein Outperform → Mkt Perform
2024-01-31 Downgrade Maxim Group Buy → Hold
2024-01-31 Downgrade Robert W. Baird Neutral → Underperform
2024-01-24 Downgrade Canaccord Genuity Hold → Sell
2023-12-14 Reiterato RBC Capital Mkts Sector Perform
2023-05-30 Iniziato William Blair Outperform
2023-05-04 Ripresa Piper Sandler Overweight
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Hold
2023-01-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-12-19 Downgrade Jefferies Buy → Hold
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-01 Aggiornamento Maxim Group Hold → Buy
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-05-06 Downgrade Robert W. Baird Outperform → Neutral
2022-05-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-02-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Reiterato JP Morgan Overweight
2022-01-27 Reiterato Morgan Stanley Underweight
2022-01-27 Reiterato RBC Capital Mkts Outperform
2022-01-27 Reiterato Stifel Hold
2022-01-27 Reiterato Wolfe Research Outperform
2022-01-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-12-09 Iniziato Wells Fargo Overweight
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-19 Downgrade Piper Sandler Overweight → Neutral
2021-09-09 Downgrade Stifel Buy → Hold
2021-09-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-07-20 Downgrade SVB Leerink Mkt Perform → Underperform
2021-07-19 Ripresa Wolfe Research Outperform
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-11 Downgrade Daiwa Securities Outperform → Neutral
2021-02-23 Aggiornamento Robert W. Baird Neutral → Outperform
2021-02-02 Reiterato H.C. Wainwright Buy
2020-12-30 Iniziato Daiwa Securities Outperform
2020-11-30 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Iniziato Bernstein Outperform
2020-10-28 Iniziato UBS Buy
2020-07-31 Reiterato H.C. Wainwright Buy
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-30 Reiterato H.C. Wainwright Buy
2020-04-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Iniziato Barclays Overweight
2020-01-31 Downgrade Robert W. Baird Outperform → Neutral
2019-11-19 Aggiornamento Guggenheim Neutral → Buy
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-09-03 Aggiornamento Goldman Neutral → Buy
2019-08-01 Downgrade Needham Buy → Hold
2019-05-23 Ripresa Citigroup Buy
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-12 Iniziato Evercore ISI In-line
2019-03-26 Aggiornamento William Blair Mkt Perform → Outperform
2019-03-19 Downgrade SVB Leerink Outperform → Mkt Perform
2019-02-06 Downgrade Maxim Group Buy → Hold
Mostra tutto

Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie

pulisher
Apr 13, 2025

Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus

Apr 13, 2025
pulisher
Apr 12, 2025

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com

Apr 12, 2025
pulisher
Apr 12, 2025

Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Apr 12, 2025
pulisher
Apr 12, 2025

Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades - The Motley Fool

Apr 12, 2025
pulisher
Apr 11, 2025

Pharma Tariffs Are Coming. Investors Underestimate the Risk. - Barron's

Apr 11, 2025
pulisher
Apr 11, 2025

Vertex researcher recognized by the Canada Gairdner International Award - Vertex Pharmaceuticals

Apr 11, 2025
pulisher
Apr 11, 2025

CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canad - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives The 2025 Canada Gairdner International Award For Pioneering Research And Discovery Of Medicines For Cystic Fibrosis - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Revolutionary CF Treatment Pioneer at Vertex Receives Top Medical Honor: How It Transforms Patient Care - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise - Insider Monkey

Apr 10, 2025
pulisher
Apr 09, 2025

‘Put On Your Life Vest’: Pharma Tariffs Are Coming - BioSpace

Apr 09, 2025
pulisher
Apr 09, 2025

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - MSN

Apr 09, 2025
pulisher
Apr 09, 2025

Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $462 From $459, Keeps Equalweight Rating - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued - Yahoo Finance

Apr 09, 2025
pulisher
Apr 09, 2025

Vertex raises pay of CEO Reshma Kewalramani by 4% to $21.5M - Fierce Pharma

Apr 09, 2025
pulisher
Apr 08, 2025

Vertex non-opioid painkiller Journavx gets mixed ICER review - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug” - Yahoo Finance

Apr 08, 2025
pulisher
Apr 08, 2025

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? - Yahoo Finance

Apr 08, 2025
pulisher
Apr 08, 2025

Is Vertex Pharmaceuticals Stock a Buy? - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Vertex secures expanded EU approval for Kaftrio - The Pharma Letter

Apr 08, 2025
pulisher
Apr 08, 2025

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe - Yahoo Finance

Apr 08, 2025
pulisher
Apr 07, 2025

Jim Cramer Nailed These 11 Stock Picks - Insider Monkey

Apr 07, 2025
pulisher
Apr 07, 2025

Vertex to Announce First Quarter 2025 Financial Results on May 5th - BioSpace

Apr 07, 2025
pulisher
Apr 07, 2025

Vertex Gains European Approval For Expanded Use Of KAFTRIO In Treating Cystic Fibrosis - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Expands Approval for Vertex's Kaftrio (VRTX) - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Vertex Pharmaceuticals Sets Key Q1 2025 Earnings Date: What Investors Must Know - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

Vertex Pharmaceuticals Says EU Approves Kaftrio Label Expansion in Cystic Fibrosis - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

EU approves expanded use of Vertex’s cystic fibrosis drug - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

2 Stocks to Buy if You're Worried About a Recession - Yahoo Finance

Apr 07, 2025
pulisher
Apr 06, 2025

Vertex Pharmaceuticals: A Look At Their Pain Therapy Program (NASDAQ:VRTX) - Seeking Alpha

Apr 06, 2025
pulisher
Apr 05, 2025

Vertex Pharmaceuticals - drugdiscoverytrends.com

Apr 05, 2025
pulisher
Apr 04, 2025

10 Best Health Care Stocks to Buy for 2025 - Money/ US News

Apr 04, 2025
pulisher
Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025
pulisher
Apr 03, 2025

Bank of America Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $567.00 - MarketBeat

Apr 03, 2025
pulisher
Apr 03, 2025

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Apr 03, 2025
pulisher
Apr 03, 2025

Vertex Pharmaceuticals: How a Human-Centric Digital Strategy Transforms Supply Chain Agility - Logistics Viewpoints -

Apr 03, 2025
pulisher
Apr 03, 2025

Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Apr 03, 2025
pulisher
Apr 03, 2025

Vertex Pharmaceuticals' Human-Centric Approach to Digital Transformation - ARC Advisory

Apr 03, 2025
pulisher
Apr 03, 2025

Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals

Apr 03, 2025
pulisher
Apr 02, 2025

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail

Apr 02, 2025
pulisher
Apr 02, 2025

Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune

Apr 02, 2025
pulisher
Apr 01, 2025

Judge Blocks Vertex From Funding Fertility Preservation Services - Bloomberg Law News

Apr 01, 2025
pulisher
Apr 01, 2025

Careers | Inclusion, Diversity and Equity - Vertex Pharmaceuticals

Apr 01, 2025
pulisher
Apr 01, 2025

Is Vertex Pharmaceuticals Gaining or Losing Market Support? - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy? - Insider Monkey

Apr 01, 2025
pulisher
Apr 01, 2025

DC court backs HHS in rejecting Vertex's proposed fertility support program for Casgevy patients - Fierce Pharma

Apr 01, 2025
pulisher
Apr 01, 2025

VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates - TradingView

Apr 01, 2025

Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$571.06
price up icon 3.05%
$606.39
price up icon 4.38%
$240.01
price up icon 0.94%
biotechnology ONC
$242.75
price up icon 5.38%
$102.34
price up icon 6.03%
Capitalizzazione:     |  Volume (24 ore):